Saturn V Capital Management LP — 13F Holdings & Portfolio

CIK 1964437 · latest 13F-HR filed 2026-08-14

Saturn V Capital Management LP manages $697.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are AMLX (11.91%), ALMS (11.76%), ABVX (9.91%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 1; 16 existing positions rose in reported value and 3 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$697.5M

Long-equity book

Holdings
23

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+3 / −1 / ↑16 / ↓3

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 75.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Aug 4, 2026.

Assets Under Management
$793.2M
Discretionary
$793.2M
Employees
6
Accounts
4
Address
823 CONGRESS AVENUE
SUITE 1030
AUSTIN, TX 78701
Phone
(415) 738-4435
Name Title / Status Ownership Type
EDWARDS, DOUGLAS, KEVIN ControlCHIEF COMPLIANCE OFFICER
since May 2023
Less than 5%Individual
TIAN, XIAOYING, (NMN) ControlLIMITED PARTNER
since Sep 2023
75% or moreIndividual
SVCM GP LLCGENERAL PARTNER
since Sep 2023
Less than 5%Domestic Entity
TIAN, XIAOYING, (NMN) Control
Indirect owner via SVCM GP LLC
MANAGING MEMBER
since Sep 2023
75% or moreIndividual
Ownership & leadership changes · 2 filings with changes since Feb 23, 2022

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Oct 13, 2023 filing
  • AddedSVCM GP LLC · GENERAL PARTNER · Less than 5%
  • AddedTIAN, XIAOYING, (NMN) · MANAGING MEMBER · 75% or more · indirect via SVCM GP LLC · control person
  • ChangedTIAN, XIAOYING, (NMN) · title MANAGING MEMBER → LIMITED PARTNER
Jun 28, 2023 filing
  • No longer listedSATURN V CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person · listed since Mar 2021
  • AddedEDWARDS, DOUGLAS, KEVIN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Feb 23, 2022 filing (earliest on record)
  • ListedSATURN V CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person
  • ListedTIAN, XIAOYING, (NMN) · MANAGING MEMBER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 16 →

Top Trims

Show all 3 →

Exited Positions

Show all 1 →

Saturn V Capital Management LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $83.0M 11.91% 4,624,101 SH
2 ALUMIS INC ALMS 022307102 $82.0M 11.76% 2,915,443 SH
3 ABIVAX SA ABVX 00370M103 $69.1M 9.91% 518,865 SH
4 VAXCYTE INC PCVX 92243G108 $49.6M 7.11% 852,914 SH
5 IMMIX BIOPHARMA INC IMMX 45258H106 $48.0M 6.89% 4,658,429 SH
6 PHARVARIS N V PHVS N69605108 $45.4M 6.52% 1,314,122 SH
7 JAZZ PHARMACEUTICALS PLC JAZZ G50871105 $38.8M 5.56% 160,938 SH
8 CELCUITY INC CELC 15102K100 $38.7M 5.55% 370,318 SH
9 DISC MEDICINE INC IRON 254604101 $38.4M 5.50% 524,730 SH
10 CANDEL THERAPEUTICS INC CADL 137404109 $34.0M 4.88% 3,303,686 SH
11 X4 PHARMACEUTICALS INC XFOR 98420X202 $32.6M 4.67% 6,973,343 SH
12 MONOPAR THERAPEUTICS INC MNPR 61023L207 $28.9M 4.14% 311,976 SH
13 DYNE THERAPEUTICS INC DYN 26818M108 $23.5M 3.37% 1,057,493 SH
14 TREVI THERAPEUTICS INC TRVI 89532M101 $19.6M 2.81% 1,052,043 SH
15 ZURA BIO LTD ZURA G9TY5A101 $12.4M 1.78% 2,101,119 SH
16 SAGIMET BIOSCIENCES INC SGMT 786700104 $11.4M 1.64% 1,479,918 SH
17 OCULIS HOLDING AG OCS H5870P102 $9.5M 1.36% 684,880 SH
18 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $7.9M 1.13% 3,869,056 SH
19 VIR BIOTECHNOLOGY INC VIR 92764N102 $7.9M 1.13% 770,643 SH
20 INVIVYD INC IVVD 00534A102 $7.3M 1.05% 8,392,288 SH
21 ALTO NEUROSCIENCE INC ANRO 02157Q109 $4.8M 0.69% 182,829 SH
22 SATELLOS BIOSCIENCE INC MSLE 80401L803 $2.7M 0.39% 350,000 SH
23 OVID THERAPEUTICS INC OVID 690469101 $1.8M 0.26% 663,060 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $697.5M 23 0001964437-26-000012
2026-03-31 2026-05-15 $552.2M 21 0001964437-26-000005
2025-12-31 2026-02-17 $544.9M 20 0001964437-26-000003
2025-09-30 2025-11-14 $456.0M 17 0001964437-25-000013
Filer Information
Address
823 CONGRESS AVENUE
SUITE 1030
AUSTIN, TX 78701-2102
Phone
(415) 738-4435
Filing Manager
Saturn V Capital Management LP
AUSTIN, TX
Signatory
Douglas K Edwards
Chief Financial Officer